Cathy R. Kessenich, DSN, ARNP
Professor of Nursing
Associate Director and MSN Program Director
Department of Nursing
University of Tampa
THIS PROGRAM WAS ORIGINALLY PRESENTED AS AN AANP LIVE GROUP LECTURE SERIES (GLS) BEGINNING SEPTEMBER 11, 2010. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE GLS, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Osteoporosis is a systemic skeletal disease characterized by decreased bone mass and compromised bone strength. The result is fragile bones and an increased risk of debilitating fractures, even after minimal trauma. Osteoporosis is a significant health problem—over half of adults over age 50 may be at risk—and the condition is usually clinically silent until a fracture occurs. Although there has been an increase in therapeutic options to treat patients who have or are at risk for osteoporosis, it remains a major health threat with staggering consequences.
Much of the burden could be avoided if at-risk individuals were identified early and offered appropriate preventative and/or therapeutic interventions immediately. However, measures to identify and treat patients who have or are at risk for osteoporosis are greatly underused in clinical practice. This educational initiative is focused on empowering nurse practitioners and providing them with the clinical knowledge, tools, and patient education strategies that will lead to better management of osteoporosis and improved patient quality of life.
Developed by the American Association of Nurse Practitioners in cooperation with
MCM Education Target Audience
This program was developed for nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
Evaluate and apply validated national and international tools/guides to stratify patients for osteoporosis and fractures.
Evaluate the clinical benefits and potential adverse effects associated with medications used for the treatment of osteoporosis.
Develop effective individualized treatment plans, including pharmacologic and non-pharmacologic therapies, to increase bone mass and reduce the risk of fractures based on the unique needs of each patient.
Apply strategies to improve patient education and adherence to osteoporosis therapies.
Dr. Kessenich has no conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Credit Statements
This program is approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1006177.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Commercial Support Statements
This activity is supported through educational grants from Amgen Inc. and Pfizer Inc.
COMPLETING THE POST TEST AND EVALUATION
When you return to the AANP CE Center, login and find the program you wish to complete. On the program’s content page you can go directly to Start Post-Test at the bottom of the page. When you have successfully completed the online post-test you will be instructed to complete the online evaluation and then receive your certificate.
If you do not have a registration (email and password) with AANP, you will be asked to register: MyAANP. Complete the short profile and create your password to continue in the CE Center. Please contact Stormy Causey, CE Coordinator, at CECenter@aanp.org with any questions.
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Nurse Practitioners, Amgen Inc., or Pfizer Inc.